TG Therapeutics (TGTX) Stock Surged After Financial Update And Milestones
TG Therapeutics, Inc. (NASDAQ: TGTX) has unveiled its financial results for the First Quarter 2024, along with noteworthy company advancements. Subsequently, there was a notable surge of 17.43% in TGTX stock, reaching $16.04 at the latest assessment. The financial report discloses that TG Therapeutics (TGTX) has recorded BRIUMVI (ublituximab-xiiy) U.S. net earnings amounting to $50.5 […]
